KYMR

MKT CAP:$7B

Kymera Therapeutics, Inc.

Market Cap

$7B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$88.07+$15.31 (+21.04%)

Apr 21, 2026

Company Details

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation syste...

CEO

Nello Mainolfi

IPO Date

Aug 21, 2020

Website

www.kymeratx.com

Key Metrics TTM

Revenue

$39M

-16.7% YoY

Net Income

-$311M

EPS (Diluted)

-$3.69

Free Cash Flow

-$234M

Revenue / Share

$0.46

Gross Margin

100.0%

Operating Margin

-891.3%

Net Margin

-794.4%

FCF Margin

-597.8%

P/S

178.3x

P/E

—

Earnings Reports

Q1 2026

May 8, 2026

PENDING

FY 2025

Feb 26, 2026

$39M-16.7%EPS -$3.69

Q4 2025

Feb 26, 2026

$3M-61.3%EPS -$0.98

Q3 2025

Nov 4, 2025

$3M-26.1%EPS -$0.94

Q2 2025

Aug 11, 2025

$11M-55.3%EPS -$0.95

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$10M	$10M	-$37M
Q2 22	$12M	$12M	-$41M
Q3 22	$10M	$10M	-$45M
Q4 22	$16M	$16M	-$39M
Q1 23	$9M	$9M	-$45M
Q2 23	$17M	$17M	-$43M
Q3 23	$5M	$5M	-$58M
Q4 23	$48M	$48M	-$19M
Q1 24	$10M	$10M	-$58M
Q2 24	$26M	$26M	-$51M
Q3 24	$4M	$4M	-$72M
Q4 24	$7M	$7M	-$81M
Q1 25	$22M	$22M	-$74M
Q2 25	$11M	$9M	-$85M
Q3 25	$3M	-$71M	-$93M
Q4 25	$3M	$79M	-$98M

Valuation

Quarter	P/S	P/E
Q1 22	109.6x	—
Q2 22	123.2x	—
Q3 22	152.1x	—
Q4 22	149.3x	—
Q1 23	149.8x	—
Q2 23	135.3x	—
Q3 23	149.2x	—
Q4 23	88.9x	—
Q1 24	88.0x	—
Q2 24	78.9x	—
Q3 24	79.8x	—
Q4 24	148.5x	—
Q1 25	118.7x	—
Q2 25	156.3x	—
Q3 25	159.8x	—
Q4 25	178.3x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$40M	-$41M
Q2 22	-$39M	-$40M
Q3 22	-$34M	-$36M
Q4 22	-$40M	-$40M
Q1 23	-$44M	-$48M
Q2 23	-$35M	-$46M
Q3 23	-$32M	-$40M
Q4 23	$8M	-$4M
Q1 24	-$40M	-$47M
Q2 24	-$43M	-$48M
Q3 24	-$50M	-$50M
Q4 24	-$62M	-$63M
Q1 25	-$79M	-$80M
Q2 25	-$60M	-$61M
Q3 25	-$27M	-$27M
Q4 25	-$67M	-$67M

Capital Expenditures

Quarter	CapEx
Q1 22	$482.0K
Q2 22	$735.0K
Q3 22	$1M
Q4 22	$373.0K
Q1 23	$4M
Q2 23	$11M
Q3 23	$8M
Q4 23	$12M
Q1 24	$7M
Q2 24	$5M
Q3 24	$189.0K
Q4 24	$936.0K
Q1 25	$467.0K
Q2 25	$695.0K
Q3 25	$181.0K
Q4 25	$106.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-48.6%	+46.1%
Q2 22	-37.8%	+21.0%
Q3 22	-53.0%	+11.1%
Q4 22	+5.7%	+11.2%
Q1 23	-1.6%	+17.7%
Q2 23	+43.4%	+14.5%
Q3 23	-50.5%	+14.3%
Q4 23	+196.7%	+22.7%
Q1 24	+8.7%	+24.3%
Q2 24	+55.3%	+27.8%
Q3 24	-20.9%	+21.9%
Q4 24	-84.6%	+31.2%
Q1 25	+114.8%	+41.7%
Q2 25	-55.3%	+25.4%
Q3 25	-26.1%	+25.6%
Q4 25	-61.3%	+14.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$8M	81.8%
Q2 22	$10M	83.6%
Q3 22	$9M	95.0%
Q4 22	$9M	55.2%
Q1 23	$9M	99.1%
Q2 23	$11M	67.7%
Q3 23	$12M	246.5%
Q4 23	$11M	22.8%
Q1 24	$12M	116.3%
Q2 24	$14M	55.9%
Q3 24	$15M	398.4%
Q4 24	$14M	186.6%
Q1 25	$14M	64.4%
Q2 25	$15M	134.3%
Q3 25	$16M	571.7%
Q4 25	$14M	505.3%

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$36M	$11M
Q2 22	$41M	$11M
Q3 22	$44M	$11M
Q4 22	$43M	$12M
Q1 23	$42M	$13M
Q2 23	$46M	$14M
Q3 23	$48M	$14M
Q4 23	$53M	$14M
Q1 24	$49M	$14M
Q2 24	$59M	$17M
Q3 24	$60M	$15M
Q4 24	$72M	$16M
Q1 25	$80M	$16M
Q2 25	$78M	$18M
Q3 25	$74M	$17M
Q4 25	$84M	$17M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$34M	$387M	$421M
Q2 22	$77M	$315M	$392M
Q3 22	$156M	$326M	$482M
Q4 22	$68M	$339M	$407M
Q1 23	$50M	$347M	$397M
Q2 23	$52M	$315M	$368M
Q3 23	$81M	$277M	$358M
Q4 23	$110M	$265M	$375M
Q1 24	$94M	$427M	$521M
Q2 24	$68M	$442M	$510M
Q3 24	$111M	$439M	$550M
Q4 24	$120M	$368M	$489M
Q1 25	$90M	$373M	$463M
Q2 25	$336M	$330M	$665M
Q3 25	$113M	$393M	$506M
Q4 25	$357M	$491M	$848M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	52M	+0.5%	+15.7%
Q2 22	52M	+0.2%	+14.8%
Q3 22	55M	+5.3%	+7.5%
Q4 22	58M	+6.1%	+12.6%
Q1 23	58M	+0.5%	+12.7%
Q2 23	58M	+0.2%	+12.7%
Q3 23	58M	+0.2%	+7.1%
Q4 23	59M	+0.2%	+1.1%
Q1 24	71M	+20.9%	+21.6%
Q2 24	73M	+3.2%	+25.3%
Q3 24	76M	+4.2%	+30.3%
Q4 24	80M	+5.1%	+36.7%
Q1 25	80M	+0.2%	+13.2%
Q2 25	80M	+0.4%	+10.1%
Q3 25	87M	+8.5%	+14.7%
Q4 25	84M	-3.3%	+5.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$68.2K	141
Q2 22	$81.7K	141
Q3 22	$67.7K	141
Q4 22	$96.6K	167
Q1 23	$56.7K	167
Q2 23	$98.9K	167
Q3 23	$28.3K	167
Q4 23	$256.1K	187
Q1 24	$55.0K	187
Q2 24	$137.2K	187
Q3 24	$20.0K	187
Q4 24	$39.3K	188
Q1 25	$117.6K	188
Q2 25	$61.0K	188
Q3 25	$14.7K	188
Q4 25	$12.0K	238

Revenue / Employee